Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Eadie

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Medical Journal of Australia|February 1, 1975
Obituary: Leonard Walter JonhstonJ Horan, F J Colahan, N Eadie
Leukemia|December 3, 2016
Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'L N Eadie, T P Hughes, D L White
Clinical Pharmacology and Therapeutics|October 11, 2013
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinibL N Eadie, T P Hughes, D L White
Plos One|August 19, 2016
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 15, 2018
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapyLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 17, 2025
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatmentsMaxim Buckley, David T Yeung, Deborah L White, et al.
Leukemia & Lymphoma|August 1, 2012
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Laura N Eadie, Verity A Saunders, Timothy P Hughes, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Plos One|February 1, 2018
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cellsLaura N Eadie, Phuong Dang, Jarrad M Goyne, et al.
Genes, Chromosomes & Cancer|July 29, 2020
MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategiesMichelle O Forgione, Barbara J McClure, David T Yeung, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Medical Journal of Australia|February 1, 1975
Obituary: Leonard Walter JonhstonJ Horan, F J Colahan, N Eadie
Leukemia|December 3, 2016
Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'L N Eadie, T P Hughes, D L White
Clinical Pharmacology and Therapeutics|October 11, 2013
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinibL N Eadie, T P Hughes, D L White
Plos One|August 19, 2016
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 15, 2018
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapyLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 17, 2025
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatmentsMaxim Buckley, David T Yeung, Deborah L White, et al.
Leukemia & Lymphoma|August 1, 2012
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Laura N Eadie, Verity A Saunders, Timothy P Hughes, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Plos One|February 1, 2018
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cellsLaura N Eadie, Phuong Dang, Jarrad M Goyne, et al.
Genes, Chromosomes & Cancer|July 29, 2020
MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategiesMichelle O Forgione, Barbara J McClure, David T Yeung, et al.
Pageof 3